Enliven Therapeutics, Inc. (ELVN): Total Assets
$476.17M
As of 2025-12-31
$910.22M
As of 2026-06-30
+78.8%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $476.17M | +46.2% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $325.76M | +19.8% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $271.87M | +226.4% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $83.30M | n/c | 2024-03-14, Balance as of period end |
| 2021-12-31 | $93.65M | +3.1% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $90.84M | +172.8% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $33.30M | n/a | 2021-03-05, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $476.17M | +46.2% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $479.51M | +250.2% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $488.62M | +23.4% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $451.45M | -26.6% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $448.38M | +172.9% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
Compare ELVN, MPLT, RYTM, ORKA side by side · Screen every company in Pharmaceutical Preparations ↗